Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And that's how young biotechs run their business. Shocker.
It's not like you guys are holding some secret numbers, it's all out there
https://ycharts.com/companies/AVXL/shares_outstanding
The most important part of the agreement is below:
Under the Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase 50,000 shares of our Common Stock on any such business day. On any day that the closing sale price of our common stock is not below $7.00 the purchase amount may be increased, at our sole discretion, to up to 75,000 shares of our common stock per purchase; on any day that the closing sale price of our common stock is not below $9.00 the purchase amount may be increased, at our sole discretion, to up to 100,000 shares of our common stock per purchase and on any day that the closing sale price of our common stock is not below $11.00 the purchase amount may be increased, at our sole discretion, to up to 125,000 shares of our common stock per purchase and on any day that the closing sale price of our common stock is not below $13.00 the purchase amount may be increased, at our sole discretion, to up to 150,000 shares of our common stock per purchase. Such purchases are hereinafter referred to as “Regular Purchases”. In no event shall Lincoln Park purchase more than $2,000,000 worth of our common stock pursuant to a Regular Purchase on any single business day. The purchase price per share for each such Regular Purchase will be equal to the lower of:
- the lowest sale price for our common stock on the purchase date of such shares; or
- the arithmetic average of the three lowest closing sale prices for our common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares.
Let me point out that Dr. Missling has dealed in a satisfactory manner with LPC before. He is a savvy financial planner who knows what he is doing.
99% of the time the therapies were targeting amyloid plaque. Indeed not a surprise they all failed. Even AF has buried the amyloid approach by now, unqualified as he is.
This has been put to rest a long time ago by the longs here.
Here's the S3 filing, show it to your friend if you want.
https://www.sec.gov/Archives/edgar/data/1314052/000161577415003018/s102056_forms3.htm
Please impress us with your DD, what do you know about the properties of A2-73? I'm all ears.
What many people don't realise is that dementia symptoms are caused also by anticonvulsants, sedatives, antidepressants and anti-anxiety medications. Great numbers of people take these all the time.
Watch this eye-opener where homeostasis is the keyword:
We need a good PR.
That conference is not listed on the website:
http://www.anavex.com/events/
Let's keep an eye on AD/PD 2017, perhaps there are still free slots for that day?
SYMPOSIUM 58 - LATE BREAKING THERAPEUTIC STRATEGIES IN AD AND PD
Hall C Date: Sunday, April 2, 2017 From: 11:45 To: 13:45
Not really news to me either. Scroll all the way down in the Company Presentation below and look under 'Key Achievements to Date and Expected Catalysts in 2016'. Presentation needs to be updated but Preparation for Phase 2/3 is checked so should be well underway.
http://www.anavex.com/files/Anavex_Presentation_Spring_2016.pdf
Maybe you have forgotten that Anavex received FDA guidance. In other words; the FDA participates in the trial design. If results are good, the FDA will be happy even with 300 patients.
https://www.warriortradingnews.com/anavex-life-sciences-avxl-stock-receives-fda-guidance/12965
A search for a cached version of Ariana's customer page on waybackmachine gives this result for February 25
https://web.archive.org/web/20170225104045/http://www.arianapharma.com/about/our-customers/
Looks pretty much the same as the screenshots taken in 2016. No Anavex logo there.
I don't remember seeing an Anavex logo on their site either.
Is it possible that Missling decided to present the 15 months data at the Oppenheimer Conference instead?
Mention of Anavex's presentation on that site can be found under Scientific Information ---> Forum Discussions.
AD/PDTM 2017 FORUM ON TRANSLATIONAL RESEARCH IN DRUG DISCOVERY FOR AD: A PLETHORA OF TARGETS: WHICH IS THE BEST, IS THERE "A BEST ONE"?
Thursday, March 30; 14:45-16:45: HALL A:
Christopher U. Missling, President & CEO, Anavex Life Sciences Corp., USA: RESTORING CELLULAR HOMEOSTASIS: DEVELOPING TARGETED THERAPIES FOR THE TREATMENT OF NEURODEVELOPMENTAL AND NEURODEGENERATIVE DISEASES UNDER THE PRECISION MEDICINE PARADIGM
http://adpd2017.kenes.com/scientific-information/forum-discussions
OK let me put it this way. TA aside, AVXL is gaining momentum here. I would be surprised if we go back to low or mid 5's next week. $7 is more likely. JMHO.
I will say this; Thanks shorty for giving me ample time to load up more at $3.20 and $4.50 :)
AVXL trading in breakout territory, presentation next wednesday and a basher shows up...What a surprise lol.
Thing to note:
Page 21
“Please note that the creation of the blank-check preferred stock has not been proposed by the Board for an anti-takeover related purpose and the Board has no knowledge of any current efforts to obtain control of the Company or to effect large accumulations of our voting stock.“
And below proposal 2 they state:
“The Board’s desire to adopt the Shareholder Rights Plan is not in response to or in anticipation of any pending or threatened take-over bid, nor to generally deter take-over bids.”
http://secfilings.nasdaq.com/efxapi/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=11922725&SessionID=KJXUqzrwwZkNa41#S105533_DEF14A_HTM_A_016
Not a poison pill then methinks.
Do we see a nice bullish W pattern completing here with the left side decline starting from $6.64 a couple weeks ago?
In all fairness, I know not of one single stock that has the potential that Anavex has. But I agree, let's just wait and see. The price will be right eventually.
After Anavex's reverse split and uplist we rocketed up, not down. That was until AF had to open his filthy mouth.
AF writes about NTRP (read; gives the 'go' signal to short sellers cabal) and your stock tanks. And you take this man seriously?
Cancer trials: 5000
Alzheimer's trials: 23
Of those 23, Anavex may soon be the only one standing.
That first video seems to be from 2015, I never saw that. Thanks for posting. I believe Paul was not allowed to take part in the trial because he had another form of dementia.
That would render them useless, so I guess not.
I wanna know too. Does a 3 months trial do justice to a placebo control?
He seems not to be aware of the Oppenheimer presentation next wednesday.
Thanks wildcard. Last week you looked at the other Alzheimer's stock SLB rate and it was at 120%. What is it now?
And already in the green :) Welcome Germ.
Don't worry Ken, IR will send you a reply..
I'm sure this man feels like he has won the lottery
https://www.facebook.com/TheProjectTV/videos/10154154448498441/?hc_ref=SEARCH
OFP, I choose my investments carefully and I feel that, given the results so far, AVXL is a no brainer.
That you interpret my moniker differently is not my problem and says more about you than me.
Because the naysayers demand it.
Anything that has Rockefeller's name attached to it, beware.
http://aangirfan.blogspot.com.es/2011/08/rockefeller.html
Can you say phantom shares?
It's lose, not loose...
You are a bit short-sighted. This is what matters more:
New Positions 16 2,359,071
Sold Out Positions 6 192,267
Increased Positions 35 3,223,322
Decreased Positions 17 296,827
67 Institutional Holders
7,508,320 Total Shares Held
Per Nasdaq.
Some people here seem to forget that Anavex is not a one-trick pony. Yes, 15 month data is important but we can soon have news about other things too.